bluebird bio presents new data from HGB-205 study of LentiGlobinTM drug product
bluebird bio announced new data from the ongoing HGB-205 clinical study evaluating its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia and severe sickle cell disease. Four patients with TDT and one patient with severe SCD have undergone infusion with the product. December 03, 2016